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1. INTRODUCTION {#dad212064-sec-0050}
===============

Alzheimer\'s disease (AD) is characterized by a complex set of molecular pathways that begin decades before symptoms start.[^1^](#dad212064-bib-0001){ref-type="ref"}, [^2^](#dad212064-bib-0002){ref-type="ref"} Changes in proteins, lipids, and many other molecular networks have been described.[^3^](#dad212064-bib-0003){ref-type="ref"}, [^4^](#dad212064-bib-0004){ref-type="ref"} The overlapping and interaction of these networks can obscure the root pathogenic mechanisms when not fully accounted for in molecular or analytical methods. The level of complexity in these networks is becoming more evident as the cumulative knowledge of AD pathogenesis has increased in the last decade. Disentangling these complexities is becoming more feasible due to the significant advances in high throughput technologies[^5^](#dad212064-bib-0005){ref-type="ref"} coupled with novel bioinformatic tools including those developed by our team.[^6^](#dad212064-bib-0006){ref-type="ref"} Recent examples applying the high throughput measurements of thousands of metabolites coupled with advanced bioinformatic approaches has comprehensively described molecular alterations and pathways in multiple diseases.[^7^](#dad212064-bib-0007){ref-type="ref"}, [^8^](#dad212064-bib-0008){ref-type="ref"}, [^9^](#dad212064-bib-0009){ref-type="ref"}, [^10^](#dad212064-bib-0010){ref-type="ref"} We apply these advances in investigating underlying metabolic changes in AD.

Metabolomic research focuses on examining metabolites, small molecules (typically \<1500 Da) that are end products of multiple biological pathways and processes. The human metabolome is estimated to contain ≈150,000 or more of such metabolites and a large fraction are still unidentified.[^11^](#dad212064-bib-0011){ref-type="ref"} Metabolomics aid in identifying downstream perturbations from the genetic and post genetic pathways reflecting a functional signature of biochemical activities that are closer to the phenotypical changes.[^12^](#dad212064-bib-0012){ref-type="ref"} Our work uses high resolution untargeted metabolomic approaches, which can be a powerful tool in describing novel and previously unknown pathways involved in AD pathogenesis.

Brain hypometabolism has been reported in symptomatic AD as well as before the onset of cognitive symptoms.[^13^](#dad212064-bib-0013){ref-type="ref"} Preliminary studies have suggested the existence of multiple metabolic changes in this prodromal stage.[^14^](#dad212064-bib-0014){ref-type="ref"}, [^15^](#dad212064-bib-0015){ref-type="ref"} However, many previous studies have either included small samples for cerebrospinal fluid (CSF) analyses,[^16^](#dad212064-bib-0016){ref-type="ref"}, [^17^](#dad212064-bib-0017){ref-type="ref"}, [^18^](#dad212064-bib-0018){ref-type="ref"} used targeted approaches, or focused on plasma profiling.[^16^](#dad212064-bib-0016){ref-type="ref"}, [^17^](#dad212064-bib-0017){ref-type="ref"}, [^18^](#dad212064-bib-0018){ref-type="ref"}, [^19^](#dad212064-bib-0019){ref-type="ref"} In this study, we conducted a case‐control untargeted high resolution metabolomic study on the CSF of a larger sample, relative to published CSF studies to date, of normal cognition (NC) and mild cognitive impairment (MCI), a prodromal state for AD. We aimed at investigating the alterations between NC and MCI in the metabolome and metabolic pathways using an established high resolution metabolomic biospecimen and data analysis pipeline. We further explored the association of these metabolic alterations with multiple disease phenotypes related to cognition, CSF amyloid beta 1‐42 (Aβ42) and tau biomarkers, and brain magnetic resonance imaging (MRI) measures.

2. METHODS {#dad212064-sec-0060}
==========

2.1. Participant description {#dad212064-sec-0070}
----------------------------

Data for the current analysis were drawn from the baseline assessment of participants in the Brain Stress Hypertension and Aging program (B‐SHARP) at Emory University. B‐SHARP participants undergo baseline cognitive assessments, neuroimaging, and lumbar punctures and are subsequently enrolled clinical studies. This analysis used data from the 185 participants enrolled from March 2016 to January 2019 who had CSF obtained during their baseline evaluations. The protocol was approved by the Emory University Institutional Review Board prior to recruitment. Each participant provided a written informed consent.

### HIGHLIGHTS {#dad212064-sec-0080}

Metabolic signature is detectable in amnestic mild cognitive impairment (MCI), a prodromal state for Alzheimer\'s disease.This signature includes dysregulation in sugars, methionine, and tyrosine metabolism.S‐adenosylmethionine is under‐ and S‐adenosylhomocysteine is overexpressed in MCI.

### RESEARCH IN CONTEXT {#dad212064-sec-0090}

Systematic review: The authors searched PUBMED and Google Scholar for previous reports of metabolomics and Alzheimer\'s disease (AD). Search terms included: mild cognitive impairment, Alzheimer\'s disease "AND" metabolism, metabolomics. This search resulted in the following findings: Prior studies have either included small samples, used targeted approaches, or focused on plasma profiling. In this study, we conducted a case‐control untargeted high resolution metabolomic study on the cerebrospinal fluid of a larger sample of normal cognition and mild cognitive impairment (MCI).Interpretation: We discovered that multiple pathways, including pathways in sugar, methionine and homocysteine, and tyrosine metabolism were dysregulated in AD. Further, features that were significantly different between MCI and normal cognition had different patterns of association with cognitive, neuroimaging, and amyloid and tau biomarkers.Future direction: These pathways offer new potential targets for AD.

The sample includes community‐dwelling adults 50 years or older with NC or amnestic MCI. Potential study participants were identified either through a referral from the Goizueta Alzheimer\'s Disease Research Center at Emory or through strategic community partnerships with grass roots health education organizations, health fairs, advertisements, and mail out announcements. An appropriate study informant, defined as an individual who has regular contact with the participant at least once a week (in person or telephone), was also identified for each participant. The potential study participant attended a screening visit, during which they underwent cognitive testing. A study physician also performed a clinical evaluation, cognitive interview, and a lumbar puncture (LP).

2.2. Cognitive diagnosis and exclusionary criteria {#dad212064-sec-0100}
--------------------------------------------------

Amnestic MCI categorization was done using modified Peterson criteria. This modification included using the Montreal Cognitive Assessment (MoCA)[^20^](#dad212064-bib-0020){ref-type="ref"} instead of Mini‐Mental State Exam.[^21^](#dad212064-bib-0021){ref-type="ref"} MCI criteria included subjective memory complaints, a MoCA \< 26, Clinical Dementia Rating (CDR) score, memory sum of boxes=0.5,[^22^](#dad212064-bib-0022){ref-type="ref"} education adjusted cutoff score on Logical Memory delayed recall of the Wechsler Memory Scale,[^23^](#dad212064-bib-0023){ref-type="ref"} and preserved Functional Assessment Questionnaire (FAQ)\<=7.[^24^](#dad212064-bib-0024){ref-type="ref"} Individuals with amnestic MCI are at high risk for progression into dementia due to AD and hence may be considered a prodromal state for AD.[^25^](#dad212064-bib-0025){ref-type="ref"}

NC was defined as having no significant memory complaints beyond those expected for age, a MoCA score [\>]{.ul}26 points, a CDR score of 0 (including 0 on the Memory Box score), and preserved FAQ \<=7. Participants were excluded if they had a history of stroke in the past 3 years, were unwilling or unable to undergo study procedures including MRI and LP, did not have a study informant, had a clinical diagnosis of dementia of any type, or abnormal serum thyroid stimulating hormone (\>10) or B12 (\<250).

2.3. Cognitive assessment and biomarker measurements {#dad212064-sec-0110}
----------------------------------------------------

Demographics (age, sex, education), anthropometrics (weight and height), medical diagnosis, and medications were collected at baseline by interview. Cognitive assessment included those described above plus Trail Making Tests (TMT Part A and B) a measure of executive function and Hopkins Verbal Learning Test (HVLT) for episodic memory. Cognitive assessment was performed by trained personnel supervised by the study neuropsychologist. After a fast of at least 6 hours, CSF samples were collected via LP using 24G Sprotte atraumatic spinal needles. Samples were collected in sterile polypropylene tubes, separated into 0.5cc aliquots, and stored at −80°C. Samples were subsequently shipped to and analyzed by the Biomarker Research Laboratory at the University of Pennsylvania (Dr. Leslie Shaw).[^26^](#dad212064-bib-0026){ref-type="ref"} CSF biomarkers: Aβ, t‐tau, and p‐tau were measured using the multiplex with the multiplex xMAP Luminex platform (Luminex Corp, Austin, TX) with Innogenetics (INNO‐BIA AlzBio3; Ghent, Belgium; for research use--only reagents) immunoassay kit--based reagents. The test--retest reliabilities are 0.98, 0.90, and 0.85 for t‐tau, Aβ, and p‐tau181p, respectively.[^26^](#dad212064-bib-0026){ref-type="ref"}

2.4. MRI brain imaging {#dad212064-sec-0120}
----------------------

Brain magnetic resolution imaging (MRIs) were also completed at Emory University (3.0 Tesla Trio MRI scanner, Siemens Medical Solutions, Malvern, PA). Anatomical images were acquired using high‐resolution three‐dimensional (3D) magnetization‐prepared rapid acquisition with gradient echo (MPRAGE). Images were then digitally saved for offline processing. Hippocampal volume and other volumetric measurements were calculated using the free surfer package with manual supervision. Quality checks were performed for each scan. Left and right hippocampal volumes were obtained and combined to derive the total hippocampal volume and cortical thickness. Intra‐cranial volume (ICV, mm^3^) was also derived from this analysis. Volumetric measurements using free surfer has been shown to provide similar estimates to a fully manual procedure.[^27^](#dad212064-bib-0027){ref-type="ref"} We used ICV‐adjusted hippocampal volume to reflect the degree of neurodegeneration for each participant.[^28^](#dad212064-bib-0028){ref-type="ref"}

2.5. Untargeted metabolomic high‐resolution metabolomics approaches and pipeline {#dad212064-sec-0130}
--------------------------------------------------------------------------------

Our metabolomic approaches used an established pipeline developed at the Clinical Biomarker Laboratory, led by Dr. Dean Jones (diagrammatic representation of this pipeline is included in Figure S1 in supporting information). High‐resolution metabolomics (HRM) was completed using established methods by an analyst blinded to sample identity.[^8^](#dad212064-bib-0008){ref-type="ref"}, [^29^](#dad212064-bib-0029){ref-type="ref"} Briefly, CSF samples were prepared and analyzed in batches of 20. Prior to analysis, CSF aliquots were removed from storage at −80°C and thawed on ice. A 65 µL aliquot of CSF was then treated with 130 µL of liquid chromatography‐mass spectrometry (LC‐MS) grade acetonitrile, equilibrated for 30 minutes on ice and centrifuged (16.1 × g at 4°C) for 10 minutes to remove precipitated proteins. The supernatant was added to an autosampler vial and maintained at 4°C until analysis. Sample extracts were analyzed using LC and Fourier transform high‐resolution mass spectrometry (Dionex Ultimate 3000, Q‐Exactive HF, Thermo Scientific). For each sample, 10 µL aliquots were analyzed in triplicate using hydrophilic interaction liquid chromatography (HILIC) with electrospray ionization source operated in positive mode. This use of complementary chromatography phases and ionization polarity has been shown to improve detection of endogenous and exogenous chemicals.[^30^](#dad212064-bib-0030){ref-type="ref"} Analyte separation was accomplished by HILIC using a 2.1 mm × 100 mm × 2.6 µm Accucore HILIC column (Thermo Scientific) and an eluent gradient (A = 2% formic acid, B= water, C= acetonitrile) consisting of an initial 1.5 minutes period of 10% A, 10% B, 80% C, followed by linear increase to 10% A, 80% B, 10% C at 6 minutes and then held for an additional 4 minutes, resulting in a total runtime of 10 minutes per injection. Mobile phase flow rate was held at 0.35 mL/min for the first 1.5 minutes, increased to 0.5 mL/min, and held for the final 4 minutes.

The high‐resolution mass spectrometer was operated in full scan mode at 120,000 resolution and mass‐to‐charge ratio (*m/z*) range 85--1275. Probe temperature, capillary temperature, sweep gas, and S‐Lens RF levels were maintained at 200°C, 300°C, 1 arbitrary units (AU), and 45 AU, respectively, for both polarities. Positive tune settings for sheath gas, auxiliary gas, sweep gas and spray voltage setting were 45 AU, 25 AU, and 3.5 kV, respectively. Raw data files were extracted and aligned using apLCMS[^31^](#dad212064-bib-0031){ref-type="ref"} with modifications by xMSanalyzer.[^32^](#dad212064-bib-0032){ref-type="ref"} Uniquely detected ions consisted of accurate mass *m/z*, retention time and ion abundance, referred to as *m/z* features. Data filtering was performed to remove *m/z* features with median coefficient of variation within technical replicates ≥75%. Additionally, only samples with Pearson correlation within technical replicates ≥0.7 were used for downstream analysis. Feature intensities for triplicates were median summarized with the requirement that at least two replicates had non‐missing values. Batch‐effect correction was performed using ComBat.[^33^](#dad212064-bib-0033){ref-type="ref"}

2.6. Metabolome‐wide association analysis {#dad212064-sec-0140}
-----------------------------------------

A feature was retained for further analysis if at least 90% of the subjects had non‐zero intensity reading in either MCI or NC groups. After exclusion, the missing values for a feature were imputed as half of the lowest signal detected for that feature across all samples. After data filtering, all intensity values were log~2~ transformed to reduce heteroscedasticity and quantile normalized to reduce systematic errors due to technical and other non‐biological factors. Metabolome‐wide association analysis was conducted using partial least squares discriminant analysis (PLS‐DA) implemented in the mixOmics[^34^](#dad212064-bib-0034){ref-type="ref"} R package and features were selected based on the variable importance for projection (VIP) criteria. *P*‐values were obtained for each feature using a permutation test. A 1000‐permutation approach was performed by randomly shuffling the group labels of subjects and performing feature selection using PLS‐DA at each iteration.[^30^](#dad212064-bib-0030){ref-type="ref"} Multiple testing correction was performed using Storey and Tibshirani false discovery rate (FDR) adjustment.[^35^](#dad212064-bib-0035){ref-type="ref"} Discriminatory features were selected using the thresholds of VIP ≥ 2, permutation derived *P* \< .05, and FDR \< 0.1. Only features that passed all three criteria were considered significantly different between the two groups. Manhattan plot was used to visualize the pattern of differential expression across all features with respect to retention time. Fold change of log~2~ transformed intensity values was calculated for each feature as the difference between the average intensity of the two groups, log~2~ FC=average~NC~‐average~MCI~. Two‐way hierarchical clustering analysis (HCA) was used to visualize the clustering pattern of discriminatory features and samples.

2.7. Pathway analysis {#dad212064-sec-0150}
---------------------

Pathway enrichment analysis was performed using mummichog (v2.0.6), which uses both *m/z* and retention time, and included discriminatory features that met the following criteria: VIP ≥ 1.5, *P* \< .05, and FDR \<0.1. A lower VIP was used to increase enrichment within the pathway and prevent information loss.[^10^](#dad212064-bib-0010){ref-type="ref"}, [^36^](#dad212064-bib-0036){ref-type="ref"} Detailed descriptions of mummichog computational procedures were previously published for V1.0.[^37^](#dad212064-bib-0037){ref-type="ref"} Discriminatory features detected in the pathways were further tested for differential expression between the NC and MCI groups using Wilcoxon rank sum test.

Additional pathway analyses were performed using Cystoscape‐based metabolomic pathway analysis and visualization using Metscape.[^38^](#dad212064-bib-0038){ref-type="ref"} MetScape is a plug‐in for Cytoscape, an open source software platform for visualizing complex networks and provides a method to use experimental data leveraged with bioinformatic databases of metabolites, genes, and pathways to display them in the context of system networks. We used that tool to provide complementary information on possible metabolic differences between MCI and NC.

2.8. Metabolite annotation and identification {#dad212064-sec-0160}
---------------------------------------------

Metabolite annotation and identification was performed using MS/MS, comparison with in‐house library of confirmed metabolites, and using xMSannotator[^33^](#dad212064-bib-0033){ref-type="ref"} with the Human Metabolome Database[^34^](#dad212064-bib-0034){ref-type="ref"} (HMDB). Discriminatory features that were associated with the significantly enriched pathways and had *P* \< .05 using the Wilcoxon rank sum test were selected for MS/MS analysis. For MS/MS, samples were analyzed using a Thermo Fusion Orbitrap high‐resolution (120,000 mass resolution) mass spectrometer (Thermo Fisher Scientific, San Diego, CA) operated in positive ion mode with 5‐minutes HILIC column chromatography and similar source conditions used for the untargeted metabolic profiling. Prior to analysis, CSF proteins were precipitated using acetonitrile:water (2:1 vol/vol) and allowed to sit on ice for 30 minutes. The supernatant was then carefully pipetted for MS/MS analysis. The tandem mass spectrometry data were processed using the *xcmsSet* and *xcmsFragments* functions in XCMS[^39^](#dad212064-bib-0039){ref-type="ref"} to extract the MS/MS fragments associated with each parent mass and the experimental spectra were compared to in‐silico fragmentation using MetFrag[^40^](#dad212064-bib-0040){ref-type="ref"} or the spectra available from mzCloud (<https://www.mzcloud.org/>).

We further annotated and confirmed identities of the selected metabolites using an in‐house library of metabolites that have been previously confirmed by comparing the retention time and MS/MS of the metabolic feature with authentic standards. Additionally, we performed computational annotation using xMSannotator[^33^](#dad212064-bib-0033){ref-type="ref"} (v1.3.2) with the HMDB[^34^](#dad212064-bib-0034){ref-type="ref"} (v3.5). xMSannotator uses adduct/isotope patterns, correlation in intensities across all samples, retention time difference between adducts/isotopes of a metabolite, and network and pathway associations for associating *m/z* features with known metabolites and categorizing database matches into different confidence levels.[^41^](#dad212064-bib-0041){ref-type="ref"} This multi‐step annotation process reduces the number of false matches compared to only *m/z*‐based database search. Metabolite identification levels were assigned using an adapted version of the criteria proposed by Schymanski et al.: (1) confirmed by MS/MS and co‐elution with authentic standards (level 1); (2) confirmed by MS/MS and matches with online databases or in‐silico predicted spectra (level 2); (3) confirmed by MS/MS at the chemical class level, but no evidence for a specific metabolite (level 3); (4) computationally assigned annotation using xMSannotator (medium or high confidence) (level 4); (5) accurate mass match (level 5).[^42^](#dad212064-bib-0042){ref-type="ref"}

2.9. Association of discriminatory features with other disease phenotypes {#dad212064-sec-0170}
-------------------------------------------------------------------------

Discriminatory metabolites associated with significantly enriched pathways were then tested for associations with three AD phenotypical or endophenotypic areas: cognitive performance (MoCA for global function, TMT A and B for executive function, and HVLT‐delayed recall for episodic memory), neuroimaging (hippocampal volume and cortical thickness as indicators of neurodegeneration) and CSF AD biomarkers Aβ~1‐42~ and total and phosphorylated tau using Spearman\'s correlation analyses. A heatmap was used to visualize the correlation patterns between significant metabolic features and these measures.

3. RESULTS {#dad212064-sec-0180}
==========

3.1. Participants {#dad212064-sec-0190}
-----------------

Of the 185 participants who provided CSF, 93 were MCI and 92 were normal controls. The basic clinical characteristics of the sample are provided in Table [1](#dad212064-tbl-0001){ref-type="table"}. The MCI group were older (*P* = .007) and had higher levels of tau and p‐tau (both *P* \< .0001), but not Aβ (*P* = .6).They also had lower cognitive performance in all measures as expected and lower hippocampal volume (*P* \< .0001).

3.2. MWAS results {#dad212064-sec-0200}
-----------------

Overall, 13,064 features were detected, and 8043 features met the data filtering criteria and were used for downstream analyses. Using PLS‐DA, 294 discriminatory features were identified using the predefined criteria (Figure [1A](#dad212064-fig-0001){ref-type="fig"}). Of those, 107 features were underexpressed and 187 features were overexpressed in MCI patients relative to NC, as shown in Figure [1A](#dad212064-fig-0001){ref-type="fig"}. Two‐way HCA using the 294 discriminatory features identified 19 clusters of samples indicating clinical and metabolic heterogeneity within the MCI group (Figure S2 in supporting information). Clusters 13, 9, and 15 (blue box) primarily comprised the MCI samples. Seventy clusters comprising features with similar abundance levels across samples were identified. Of the 294 features, 94 were successfully matched to known metabolites in HMDB using xMSannotator with an annotation confidence score of medium or high (Table S1 in supporting information).

![A, Manhattan plot shows the variable importance for projection (VIP) and mass‐to‐charge ratio (*m/z*) of 8043 features. A total of 294 features were significantly different between mild cognitive impairment (MCI) cases (n = 93) and controls (n = 92) by partial least squares discriminant analysis (PLS‐DA) using a VIP measure of 2.0 or greater (threshold indicated by horizontal line). One hundred eighty seven metabolic features increased (red dots) and 107 decreased (blue dots) in MCI patients compared to controls are indicated. Metabolite classes detected at different retention time segments are annotated in the boxes. B, Pathways altered in MCI compared to normal controls. Pathway analysis was performed using Mummichog 2.0.6 on the 1049 features identified by PLS‐DA with a VIP ≥ 1.5](DAD2-12-e12064-g001){#dad212064-fig-0001}

3.3. Pathway analysis {#dad212064-sec-0210}
---------------------

To enhance the coverage of metabolites for pathway enrichment analyses and to prevent information loss, 1049 discriminatory features were included using the less stringent criteria of VIP \>1.5, *P* \< .05, and FDR \<0.1. We identified 13 pathways that were perturbed between the MCI and normal control groups, which are shown in Figure [1B](#dad212064-fig-0001){ref-type="fig"}. The top four pathways were related to bioenergetics and glucose metabolism: N‐glycan (*P* = .0007), sialic acid (*P* = .0014), amino‐sugars (*P* = .0042), and galactose (*P* = .0054) metabolism. Keratan sulfate (*P* = .0173), methionine (*P* = .0081), cyanocobalamin (*P* = .0106), tyrosine (*P* = .0193), purine (*P* = .0352) and biopterine (*P* = .0275) were also differentially activated between the two groups. Within the enriched pathways that were significantly different between NC and MCI, 15 features with an identification confidence of 1 to 5 were differentially expressed and are shown in Table [2](#dad212064-tbl-0002){ref-type="table"}. These features were then included in the Metscape analysis and visualization, leading to a signature that includes increased expressions of features related to sugar metabolism/bioenergetics, homocysteine, tyrosine and biopterin pathways, and lower expression of methionine. The final networks with relevant signature features are provided in Figure [2](#dad212064-fig-0002){ref-type="fig"}. The box plots for these 15 features are also provided in Figure [3](#dad212064-fig-0003){ref-type="fig"}. The complete list of features in these analyses is provided in Table S2 in supporting information.

###### 

Results of the pathway enrichment analysis with the significant features and associated pathways in the normal versus MCI groups

  *m/z*      time (s)   Feature name (KEGG compound name)                                                                      Pathway(s)[^a^](#dad212064-tbl2-note-0001){ref-type="fn"}                                                                                        Fold change[^d^](#dad212064-tbl2-note-0009){ref-type="fn"}   VIP    Wilcoxon P   Metabolite identification level[^c^](#dad212064-tbl2-note-0003){ref-type="fn"}   Adduct
  ---------- ---------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------ ------ ------------ -------------------------------------------------------------------------------- ------------
  173.0434   52         L‐Ribulose (C00508)[^b^](#dad212064-tbl2-note-0002){ref-type="fn"}                                     Tyrosine metabolism; Purine metabolism                                                                                                           −0.1642                                                      3.30   0.0001       3                                                                                M+Na\[1+\]
  205.0682   62         D‐Sorbitol (C00794 )[^b^](#dad212064-tbl2-note-0002){ref-type="fn"}                                    Galactose metabolism                                                                                                                             −0.124                                                       1.97   0.0025       5                                                                                M+Na\[1+\]
  365.1054   164        Maltose (C00208 )[^b^](#dad212064-tbl2-note-0002){ref-type="fn"}                                       Sialic acid metabolism; Galactose metabolism                                                                                                     −0.2469                                                      2.81   0.0055       5                                                                                M+Na\[1+\]
  385.1303   73         S‐Adenosylhomocysteine (C00021)                                                                        Methionine and cysteine metabolism; Vitamin B12 (cyanocobalamin) metabolism; Urea cycle/amino group metabolism; Tyrosine metabolism              −0.2034                                                      2.15   0.0167       1                                                                                M+H\[1+\]
  517.9829   81         7,8‐Dihydroneopterin 3′‐triphosphate (C04895)[^b^](#dad212064-tbl2-note-0002){ref-type="fn"}           Biopterin metabolism                                                                                                                             −0.6569                                                      2.32   0.0217       5                                                                                M+Na\[1+\]
  255.1076   68         Galactosylglycerol (C05401)                                                                            Sialic acid metabolism; Galactose metabolism                                                                                                     −0.4977                                                      2.72   0.0231       4                                                                                M+H\[1+\]
  260.0538   57         N‐Acetyl‐D‐glucosamine 6‐phosphate (C00357)[^b^](#dad212064-tbl2-note-0002){ref-type="fn"}             Aminosugars metabolism                                                                                                                           −0.1686                                                      2.05   0.0248       5                                                                                M+H\[1+\]
  223.0826   53         Salsolinol 1‐carboxylate (C06160)                                                                      Tyrosine metabolism                                                                                                                              −0.374                                                       2.22   0.0271       4                                                                                M+H\[1+\]
  708.2568   255        N‐acetyl‐alpha‐D‐glucosamine (C00043)[^b^](#dad212064-tbl2-note-0002){ref-type="fn"}                   N‐Glycan degradation; Keratan sulfate degradation                                                                                                −0.308                                                       2.15   0.0289       4                                                                                M+H\[1+\]
  399.1444   145        S‐Adenosylmethionine (C00019)                                                                          Methionine and cysteine metabolism; Vitamin B12 (cyanocobalamin) metabolism; Urea cycle/amino group metabolism; Tyrosine metabolism              0.3296                                                       2.17   0.0334       1                                                                                M+H\[1+\]
  384.1499   231        beta‐D‐Galactosyl‐1,4‐N‐acetyl‐D‐glucosamine (C00611)[^b^](#dad212064-tbl2-note-0002){ref-type="fn"}   N‐Glycan Degradation; Aminosugars metabolism; Galactose metabolism                                                                               −0.1902                                                      2.02   0.0357       5                                                                                M+H\[1+\]
  221.042    61         Vanillylmandelic acid (C05584)                                                                         Tyrosine metabolism                                                                                                                              −0.5378                                                      1.92   0.0365       4                                                                                M+Na\[1+\]
  799.6688   37         Levothyroxine (C01829)                                                                                 Tyrosine metabolism                                                                                                                              −0.7153                                                      2.31   0.0416       4                                                                                M+Na\[1+\]
  277.0894   67         3‐beta‐D‐Galactosyl‐sn‐glycerol (C03692)[^b^](#dad212064-tbl2-note-0002){ref-type="fn"}                Sialic acid metabolism; Galactose metabolism                                                                                                     −0.1336                                                      2.18   0.0474       4                                                                                M+Na\[1+\]
  244.0797   49         GlcNAc (C00140)[^b^](#dad212064-tbl2-note-0002){ref-type="fn"}                                         N‐Glycan degradation; Sialic acid metabolism; Aminosugars metabolism; Galactose metabolism; Keratan sulfate degradation; Hyaluronan Metabolism   −0.0803                                                      2.22   0.0507       5                                                                                M+Na\[1+\]

Some compounds were matched or involved in multiple pathways.

These features had multiple chemical names or were matched to multiple metabolites in the databases (we report the KEGG compound name involved in the significant pathway).

Description of metabolite identification levels (adapted from Schymanski et al.[^42^](#dad212064-bib-0042){ref-type="ref"}):

Level 1: confirmed by MS/MS and co‐elution with authentic standards

Level 2: confirmed by MS/MS and matches with online databases or in‐silico predicted spectra

Level 3: confirmed by MS/MS at the chemical class level, but no evidence for a specific metabolite

Level 4: computationally assigned annotation using xMSannotator (medium or high confidence)

Level 5: accurate mass match

(log2; NC vs MCI) ‐ve: lower in NC +ve: higher in NC.

Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; MCI, mild cognitive impairment; MS/MS, tandem mass spectrometry; *m/z*, mass‐to‐charge ratio; NC, normal control; VIP, variable importance for projection

John Wiley & Sons, Ltd.

![Overall metabolomic networks and related features comprising the metabolomic signature in the cerebrospinal fluid of individuals with mild cognitive impairment (MCI). The image was obtained using Metscape Plug‐in for Cytoscape using the 15 features included in the MCI signature along with the fold change and *P*‐value and the Compound‐Reaction‐Enzyme‐Gene option selected. The Network is then built from the underlying data by finding compounds that participate in reactions that are catalyzed by enzymes that are encoded by genes](DAD2-12-e12064-g002){#dad212064-fig-0002}

![Box plots for the 15 differentially expressed features identified in the cerebrospinal fluid of individuals with mild cognitive impairment. Green box plots are in the methionine pathway, brown in the sugar metabolism pathways, purple in the tyrosine metabolism pathway, and blue in the biopterin pathway](DAD2-12-e12064-g003){#dad212064-fig-0003}

3.4. Correlation with disease phenotype {#dad212064-sec-0220}
---------------------------------------

We then explored the associations between these signature features with disease phenotypes. These results are shown in Figure [4](#dad212064-fig-0004){ref-type="fig"}. Increased expression of bioenergetics and glucose metabolism were associated with higher tau and ptau but also with lower cognitive performance, hippocampal volume, and cortical thickness. Sugar metabolism dysregulations were associated with increased tau, and ptau. Further, 5 of these features were associated with decreased cortical thickness; hippocampal volume; and cognitive performance on MoCA, TMT, and delayed recall. S‐adenosylhomocysteine (SAH) was associated with lower MoCA scores and decreased cortical thickness. In the tyrosine pathway, salsolinol‐1‐carboxylate was associated with higher tau and ptau whereas Vanillylmandelic acid (VMA) was associated with lower MoCA score. Finally, features in the biopterin pathway were not associated with any disease phenotype. Detailed results are provided in Table S3 in supporting information. Correlation with demographics are also provided in Table S4 in supporting information.

![Correlations between significant features and disease phenotypes. Spearman correlation coefficients. Red indicates positive correlations and blue indicates negative correlations. Correlations with *P* ≥0.05 are marked in gray. ^\*\*^These Features had multiple chemical names or were matched to multiple metabolites in the databases (we report the KEGG compound name involved in the significant pathway)](DAD2-12-e12064-g004){#dad212064-fig-0004}

4. DISCUSSION {#dad212064-sec-0230}
=============

This study of untargeted HRM identified a CSF signature of amnestic MCI characterized by dysregulation of multiple pathways including sugar, homocysteine/methionine, and tyrosine metabolism. Multiple features within this signature were associated with increased total tau and ptau biomarkers and lower scores on cognitive measures, hippocampal volume, and cortical thickness.

Although targeted metabolomic approaches have been used in multiple tissues and samples such as Biocrates AbsoluteIDQ‐p180 kit,[^43^](#dad212064-bib-0043){ref-type="ref"} untargeted metabolomics in the CSF have been less common. The latter can be complementary to prior targeted platforms and plasma analyses and may identify new markers or new potential therapeutic targets in AD. The recent advance in MS technology and related bioinformatics have enhanced the potential for the application of metabolomics in AD.[^44^](#dad212064-bib-0044){ref-type="ref"} Indeed, over the last decade reports using untargeted metabolomics have suggested a significant previously unrecognized metabolic derangement in AD *post mortem* brains, plasma, and to a lesser extent CSF.[^45^](#dad212064-bib-0045){ref-type="ref"}, [^46^](#dad212064-bib-0046){ref-type="ref"} Our study adds to these reports by confirming and expanding on previously described impaired pathways or identifying new ones. We discuss these in the next sections.

Multiple studies have suggested an association between AD and impaired glucose metabolism that may be pronounced in those with type 2 diabetes and insulin resistance.[^47^](#dad212064-bib-0047){ref-type="ref"}, [^48^](#dad212064-bib-0048){ref-type="ref"} Prior fluorodeoxyglucose‐positron emission tomography (FDG‐PET) scans have suggested decreased brain metabolism across the spectrum of AD.[^49^](#dad212064-bib-0049){ref-type="ref"}, [^50^](#dad212064-bib-0050){ref-type="ref"} Our study suggests that in the CSF of those with MCI, there was evidence for dysregulation of multiple glucose metabolism pathways and related increase in glucose metabolism byproducts. Taken together, the increase in CSF features of sugar metabolism pathways coupled with the previously reported brain hypometabolism may in part be explained by a lower brain glucose uptake, for example, secondary to glucose uptake transporter impairment,[^51^](#dad212064-bib-0051){ref-type="ref"}, [^52^](#dad212064-bib-0052){ref-type="ref"} leading to increased CSF levels. An alternative explanation is that the possible central insulin resistance reported in AD is associated with increases in metabolic by‐products in the brain and CSF. This is further supported by our observation that these increased metabolic features are associated with greater tau measures and with lower performance on cognitive assessments, hippocampal volume, and cortical thickness. Taken together, our finding may offer support for multiple sugar metabolism pathways as therapeutic targets in AD.

Our observation that alterations in pathways related to methionine and homocysteine metabolism is of great interest. Specifically, S‐adenosylmethionine (SAM) was underexpressed and SAH was overexpressed in CSF of the MCI participants. SAM is a key molecule in the methionine cycle involved in nucleic acid and protein metabolism and synthesis. SAH is formed by demethylation of SAM. Prior reports suggest that SAM is decreased and SAH is increased in CSF of AD and related to tau biomarkers.[^53^](#dad212064-bib-0053){ref-type="ref"} However, in this study only SAM was related to additional disease phenotypes including cognitive measures and cortical thickness. Nevertheless, this untargeted approach suggests that homocysteine‐methionine pathways are dysregulated in the prodromal stages of AD.

We identified perturbations in tyrosine pathways with overlapping features in the purine, methionine, and homocysteine pathways, including SAM, SAH, VMA, and thyroxine. These cycles are involved in catecholamine and serotonin neurotransmitter systems and might be altered in AD.[^54^](#dad212064-bib-0054){ref-type="ref"} A prior CSF analysis in a smaller number of MCI using a targeted metabolomic approach suggested a similar finding of impairments in methionine and tyrosine pathways.[^55^](#dad212064-bib-0055){ref-type="ref"} Despite the difference between the groups in this pathway, there were minimal associations with the other disease measures.

There are multiple advantages to this study including the untargeted and advanced bioinformatic approaches, which allowed us to consider many pathways and features, the comparably larger number of samples with CSF, and the availability of multiple additional disease phenotypes that offer greater confidence in the associations with MCI.

The limitations include the cross‐sectional design and the number of identified features that could not be matched to known metabolites or matched to multiple metabolites, which is a major bottleneck in untargeted metabolomics.[^6^](#dad212064-bib-0006){ref-type="ref"} Even with identified metabolites, the certainty of feature identity is another limitation to untargeted metabolomic approaches. We used MS/MS with an in‐house library of confirmed metabolites in the Clinical Biomarker Lab where these analyses were performed using authentic standards to confirm these identities and we provide a standard scale of confidence in all our results. This coupled with advanced bioinformatics tools for metabolite identification and annotation enhanced the reliability of the identity of our metabolites compared to many prior untargeted studies.

Clinical translations of these findings are important. The key pathways that are perturbed in AD are potential targets for existing or new drug developments. For example, insulin and other antidiabetic agents may address the sugar metabolism abnormalities identified in this analysis.[^56^](#dad212064-bib-0056){ref-type="ref"}, [^57^](#dad212064-bib-0057){ref-type="ref"} Drugs that may restore balance between SAM and SAH or enhance tyrosine metabolism may also be of relevance in drug development of AD.[^58^](#dad212064-bib-0058){ref-type="ref"}

5. CONCLUSION {#dad212064-sec-0240}
=============

In this untargeted metabolomic study of CSF, we identified a metabolic signature characterized by impairments in sugar metabolism and methionine, homocysteine, and tyrosine pathways in MCI. These offer insight into the metabolic alterations that occur in predementia stages of AD and offer potential therapeutic targets.

###### 

Characteristics of the overall sample by the two groups, normal cognition and mild cognitive impairment (MCI)

  Characteristic                          Overall (n = 185)    Normal cognition (n = 92)   Mild cognitive impairment (n = 93)   *P* value
  --------------------------------------- -------------------- --------------------------- ------------------------------------ -----------
  **Age (years)**                                                                                                               
  Mean ± SD (N)                           64.4 ± 8.2 (185)     62.7 ± 7.1 (92)             66.1 ± 8.9 (93)                      .0071
  **Sex**                                                                                                                       
  Female                                  116 (62.7)           62 (67.4)                   54 (58.1)                            .19
  Male                                    69 (37.3)            30 (32.6)                   39 (41.9)                            
  **Race**                                                                                                                      
  White                                   117 (63.2)           63 (68.5)                   54 (58.1)                            .24
  Black or African American               65 (35.1)            27 (29.3)                   38 (40.9)                            
  Other                                   3 (1.6)              2 (2.2)                     1 (1.1)                              
  **Education (years)**                                                                                                         
  Mean ± SD (N)                           16.3 ± 2.9 (179)     16.6 ± 3.0 (92)             15.9 ± 2.9 (87)                      .23
  **Smoking status**                                                                                                            
  Never                                   44 (37.9)            32 (43.8)                   12 (27.9)                            .0014
  Current                                 21 (18.1)            6 (8.2)                     15 (34.9)                            
  Past                                    51 (44.0)            35 (47.9)                   16 (37.2)                            
  **EtOH consumption**                                                                                                          
  Current                                 88 (89.8)            66 (93.0)                   22 (81.5)                            .09
  Never or remote                         10 (10.2)            5 (7.0)                     5 (18.5)                             
  **Body mass index (kg/m^2^)**                                                                                                 
  Mean ± SD (N)                           27.3 ± 5.5 (178)     27.4 ± 5.0 (92)             27.3 ± 6.0 (86)                      .66
  **Systolic blood pressure (mm Hg)**                                                                                           
  Mean ± SD (N)                           128.9 ± 18.1 (179)   129.6 ± 19.3 (92)           128.1 ± 16.8 (87)                    .80
  **Diastolic blood pressure (mm Hg)**                                                                                          
  Mean ± SD (N)                           75.1 ± 12.4 (179)    76.9 ± 12.1 (92)            73.1 ± 12.5 (87)                     .037
  **Pulse rate, beats per min**                                                                                                 
  Mean ± SD (N)                           67.8 ± 10.8 (179)    66.9 ± 10.0 (92)            68.8 ± 11.5 (87)                     .30
  **Hypertension**                                                                                                              
  Yes                                     79 (49.7)            52 (57.8)                   27 (39.1)                            .020
  No                                      80 (50.3)            38 (42.2)                   42 (60.9)                            
  **High cholesterol**                                                                                                          
  Yes                                     70 (44.6)            43 (48.9)                   27 (39.1)                            .22
  No                                      87 (55.4)            45 (51.1)                   42 (60.9)                            
  **Diabetes mellitus**                                                                                                         
  Yes                                     21 (13.1)            11 (12.2)                   10 (14.3)                            .70
  No                                      139 (86.9)           79 (87.8)                   60 (85.7)                            
  **Heart disease**                                                                                                             
  Yes                                     13 (8.2)             6 (6.7)                     7 (10.1)                             .43
  No                                      146 (91.8)           84 (93.3)                   62 (89.9)                            
  **Congestive heart failure**                                                                                                  
  Yes                                     4 (2.5)              1 (1.1)                     3 (4.3)                              .20
  No                                      155 (97.5)           89 (98.9)                   66 (95.7)                            
  **Depression**                                                                                                                
  Yes                                     47 (29.4)            20 (22.2)                   27 (38.6)                            .024
  No                                      113 (70.6)           70 (77.8)                   43 (61.4)                            
  **Atrial fibrillation or arrythmias**                                                                                         
  Yes                                     20 (12.7)            11 (12.4)                   9 (13.2)                             .87
  No                                      137 (87.3)           78 (87.6)                   59 (86.8)                            
  **MOCA, score**                                                                                                               
  Mean ± SD (N)                           24.3 ± 3.7 (162)     26.6 ± 2.6 (92)             21.3 ± 2.8 (70)                      \<.0001
  **HVLTR, delayed recall**                                                                                                     
  Mean ± SD (N)                           8.1 ± 3.2 (161)      9.7 ± 2.0 (92)              6.0 ± 3.4 (69)                       \<.0001
  **Trail Part A (seconds)**                                                                                                    
  Mean ± SD (N)                           39.3 ± 16.6 (162)    34.9 ± 11.1 (92)            45.1 ± 20.6 (70)                     .0008
  **Trail Part B (seconds)**                                                                                                    
  Mean ± SD (N)                           108.8 ± 67.1 (161)   83.3 ± 41.0 (92)            142.8 ± 79.3 (69)                    \<.0001
  **Ab42 (pg./dl)**                                                                                                             
  Mean ± SD (N)                           255.5 ± 83.2 (183)   256.0 ± 61.1 (91)           255.1 ± 100.8 (92)                   .61
  **tau (pg./dl)**                                                                                                              
  Mean ± SD (N)                           60.4 ± 35.8 (183)    48.4 ± 20.6 (91)            72.2 ± 43.2 (92)                     \<.0001
  **Ptau (pg/dl)**                                                                                                              
  Mean ± SD (N)                           15.7 ± 9.5 (180)     12.3 ± 6.5 (90)             19.0 ± 10.9 (90)                     \<.0001
  **Total hippocampal volume**                                                                                                  
  Mean ± SD (N)                           7303 ± 1046 (139)    7654 ± 881.8 (80)           6828 ± 1071 (59)                     \<.0001

Abbreviations: EtOH, ethyl alcohol; HVLTR, Hopkins Verbal Learning Test‐Revised; MOCA, Montreal Cognitive Assessment; SD, standard deviation.
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